On September 19, a delegation including Lv Yang, Manager of NovaQuest USA; Mr. Muto, General Manager of Mitsui & Co., Ltd. Shenzhen Company; Li Zhe, Manager of Mitsui & Co., Ltd. Beijing Company; Wang Jiannan, General Manager of Shenzhen Xinyang Investment Management Co., Ltd.; Chen Lili, Assistant to the General Manager; and Li Ze'en, Assistant to the General Manager of Shenzhen Beimei Pharmaceutical Co., Ltd. visited Shenzhen Cell Valley for inspection and exchange. Shenzhen Cell Valley's Chairman and General Manager Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, General Office Director Luan Zhishi, Assistant to the Chairman Wei Zheng, R&D Department Head Zhao Lijun, and Market Expansion Department Head Sun Rui warmly received them. Both parties held discussions on planned cooperation to explore international markets.

First, accompanied by Chairman Professor Shi Yuanyuan, the Chinese and Japanese entrepreneurs visited the Smart Exhibition Hall, GMP production workshops, and R&D laboratories, gaining a preliminary understanding of the company's founding background, founder team, CAR-T therapy development history, strategic layout, and innovative service platform construction.

During the symposium, through analysis of the international market environment and pain points under the rapidly increasing development trend of the cell and gene therapy industry, Chairman Professor Shi Yuanyuan focused on introducing Shenzhen Cell Valley's technological breakthroughs and innovative achievements in connecting the upstream and downstream of cell and gene therapy. As the only one-stop CRO/CDMO service provider in China mastering industrial-grade retroviral vector technology (including PackRV-SE and other systems), the company has now completed effective layouts in Shenzhen, Beijing, and Zhongshan, capable of providing professional, efficient, and comprehensive one-stop full-industry-chain services covering early-stage R&D, vector design, virus production, cell production, and regulatory submission assistance. In the future, while adhering to the corporate mission of "Cells Benefit All, Genes Create the Future," the company will explore overseas markets, fully leverage the industrialization advantages of retroviral vectors in cell therapy drugs, and benefit cancer patients worldwide. Mitsui & Co., as one of Japan's five major trading companies, has business sectors spanning multiple fields and covering countries including Europe, America, Japan, and Southeast Asia. NovaQuest, as Mitsui's subsidiary focused on pharmaceutical investment, possesses rich experience and channel resources in R&D pipeline investment. Both parties can fully build communication bridges, create shared resource platforms, leverage inter-enterprise advantages, deepen cooperation, achieve complementarity in channels, technology, products, and policies, and jointly contribute to the development of the cell and gene therapy field.

This Sino-Japanese entrepreneur inspection and exchange event was successfully held, with both parties expressing expectations for future development and cooperation, laying a solid foundation for promoting future collaboration, providing new possibilities for the treatment of cancer and other difficult diseases and medical progress, and making positive contributions to the high-quality development of the cell and gene therapy industry.

Mitsui & Co., Ltd. is one of Japan's largest general trading companies, established on July 1, 1876. In 2023, Mitsui & Co. ranked 93rd in the Fortune Global 500. Currently, it has over 10,000 employees, more than 1,000 subsidiaries, and 226 offices in 93 countries and regions worldwide. Most of the group's subsidiaries engaged in chemicals and raw materials have merged to form Mitsui Chemicals, while other members are also involved in banking, construction, mining, and real estate industries.

Over more than a century since its inception, Mitsui & Co., Ltd. has cultivated diverse industrial capital in extensive fields—including food, machinery, energy, textiles, materials, and finance—to adapt to the demands of the times. The Mitsui Group has established a vast industrial conglomerate comprising world-renowned companies such as Toyota Motor Corporation and Toshiba Corporation. In 2001, the core enterprise of the Mitsui Group, "Sakura Bank," merged with the core bank of the Sumitomo Group, "Sumitomo Bank," to establish Sumitomo Mitsui Banking Corporation.